Inhibrx (INBX) Director Kristiina Vuori Receives 10,000-Share Option Award

What Happened

• Kristiina Vuori, a director of Inhibrx Biosciences, was granted a derivative award of 10,000 optioned shares on June 3, 2026. The grant is reported at $0.00 (no cash paid on grant). A footnote states these options will be fully exercisable on June 3, 2027, contingent on continued service through that date.
• This filing is an amended Form 4 that restates the original Form 4 filed June 4, 2026 to correct the number of options issued (administrative error).

Key Details

• Transaction date: June 3, 2026; Reported in amended filing dated Sept 18, 2026.
• Transaction type: Grant/Award (derivative option) — 10,000 shares; reported price $0.00; reported value $0.
• Vest/Exercise: Fully exercisable June 3, 2027, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Amendment: This Form 4 amends the June 4, 2026 filing to correct the number of options granted (administrative correction).

Context

• This was an option award, not an open-market purchase or sale — no immediate cash change or share sale. The options do not appear to have been exercised or sold at grant.
• Director option awards are common as compensation; the amendment corrects the originally reported grant size. The original Form 4 was filed June 4, 2026; this Sept 18 filing updates that record.